INMARSAT
23.5.2023 09:01:35 CEST | Business Wire | Press release
Inmarsat has announced the next chapter of its market-leading Jet ConneX (JX) inflight broadband solution, with a new range of service plans introduced to redefine gold standard connectivity in the business aviation market and satisfy even the most data-hungry users for many years to come.
Launched as part of Inmarsat’s JX Evolution programme, these latest service plans are available for new and existing customers to order today, marking a step-change in performance that is backed by guaranteed speeds and Inmarsat’s hallmark consistent customer experience.
The new service plans offer enhanced performance using Jet ConneX’s existing, highly successful JetWave terminal by Inmarsat’s partner Honeywell, and will also be compatible with three upcoming next-generation terminals being developed by Satcom Direct, Orbit and Honeywell. Satcom Direct’s Plane Simple Ka-band system has commenced flight testing and is expected to enter service later this year.
All three next-generation terminals use innovative technology and lightweight designs to optimise performance, reduce costs, and simplify installation and maintenance. Their reduced size and weight make them suitable for various types of business jets, creating new opportunities in the fast-growing super midsize aircraft market, which shares many of the same connectivity requirements as large aircraft.
Jet ConneX customers will also benefit from seven more Inmarsat satellite payloads entering service by 2025, increasing its Ka-band network fleet to 12. This includes two Inmarsat-6s, both of which have already launched, followed by two payloads in highly elliptical orbit, enabling the world’s only commercial mobile broadband service for flights in higher latitudes and across the Arctic. Three additional satellites will then launch in geostationary orbit, adding further speed, capacity, and resilience.
The combination of next generation terminals and Inmarsat’s fast-growing satellite network will enable speeds up to 100 Mbps, for top tier customers that demand the highest level ‘office-in-the-sky’ experience.
The new Jet ConneX service plans are available through Inmarsat’s global business aviation distribution network, which consists of Satcom Direct, Collins Aerospace and Honeywell.
Kai Tang, Inmarsat’s Head of Business Aviation, said “Jet ConneX is renowned for delivering a very high standard of service and these transformative new plans once again highlight Inmarsat’s continued focus on staying ahead of market expectations. This provides customers with reassurance that our connectivity will keep pace with their long-term needs. Importantly, as these include the first plans to use our new satellites and terminals, it also offers a glimpse into future capabilities and provides certainty that their investment in our technology is future-proofed.
“These service plans have been specifically designed to deliver even greater value and performance based on unique insights into usage of our inflight broadband service. This build-up approach is unique to Inmarsat and cannot be replicated by others in the market, some of which have a tendency to over promise and under deliver, either from the start or as their networks fill and performance degrades.
“Crucially, this is only the next step for us. We will continue to assess usage and adapt accordingly, with even more flexible options to be announced later this year.”
Since entering commercial service in November 2016, Jet ConneX has been activated on more than 1,400 business jets: offering the same reliable, consistent and high-speed broadband that was previously only available on the ground. Passenger usage of Jet ConneX increased to record levels since the pandemic, testament to fast-growing expectations from users, who use everything from video streaming and live TV to conference calls and other business activities. JX’s most powerful service plans will now enable passengers to simultaneously connect more devices and enjoy unchallenged access to the most data-hungry applications - including high-definition video conferencing - without compromising on its proven characteristics of consistency, reliability, resilience, and seamless global availability.
Inmarsat’s 2023 global survey of business aviation professionals - conducted in partnership with Corporate Jet Investor (CJI) - found that 82% of respondents believe inflight connectivity has evolved from a luxury option for some, to a key requirement for the majority of passengers. The results, published at the European Business Aviation Convention & Exhibition (EBACE) this week, show the three most important factors when selecting a connectivity system, in order, were consistent performance, 100% route coverage, and high speed.
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
